45 results about "Cholinergic system" patented technology

The invention discloses application of homomangiferin in preparing pharmaceuticals for preventing senile dementia and hypomnesis. Researches shows that homomangiferin can improve damaged learning and memory ability of APP (amyloid protein precursor) transgenic mice evidently, and can improve relatively-long-term memory in short-term memory of the APP transgenic mice. The homomangiferin can increase content of Ach (acetylcholine), improve activity of CHAT (choline acetyl transferase) and inhibit activity of AchE (acetylcholinesterase), and accordingly indexes in terms of APP transgenic dementia model pathology, cholinergic system, cell apoptosis and the like can be improved. The homomangiferin and homomangiferin compositions can be used for preparing pharmaceuticals for preventing senile dementia and hypomnesis.

A method for detecting zebrafish M3 receptor protein based on determination of p38MAPK protein expression comprises the following steps: (1), preparing a zebrafish brain tissue protein sample; (2), performing SDS (sodium dodecyl sulfate) gel electrophoresis; (3), performing film transferring; (4), closing; (5), performing primary and secondary antibody inoculation; (6), performing rendering reaction; (7), calculating M3 receptor variation results. The technical defect that traditional zebrafish M3 receptor detection is limited to zero specific antibody and accordingly is unable to use western immunoblotting is overcome, the use of p38MAPK phosphorylation level to determine changes in zebrafish M3 receptor protein content is provided for the first time, and the method is high in sensitivity, good in stability and free of complex equipment; meanwhile, the method is simple and quick to perform, high in specificity and low in cost; internal acting mechanism of a cholinergic system is studied in terms of molecules, and in connection with study on zebrafish behavior changes, finally water quality can be estimated and monitored online in real time.

The present invention relates to novel pyridylether derivatives which are cholinergic ligands at nicotinic Ach receptors. The compounds of the invention are useful for the treatment of conditions, disorders, or diseases involving the cholinergic system of the central nervous system, pain, inflammatory diseases, diseases caused by smooth muscle contractions and as assistance in the cessation of chemical substance abuse.